+62.0%
SLV vs MRNA
+511.3%
-449.3%
-52.3%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | -1.2% | -2.2% | +1.0% | -1.1% |
| 7D | -0.3% | +5.5% | -5.8% | -0.6% |
| 30D | +6.7% | +158.7% | -152.0% | -4.5% |
| 3M | -10.7% | +182.1% | -192.8% | -22.6% |
| 6M | -20.6% | +151.8% | -172.4% | -29.9% |
| YTD | -7.1% | +393.6% | -400.7% | -26.5% |
| 1Y | +62.0% | +499.5% | -437.5% | +25.6% |
| All | +62.0% | +511.3% | -449.3% | +25.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling